A szöveti angiotenzinkonvertáló enzim szerepe a cardiovascularis betegségekben

Translated title of the contribution: Role of tissue angiotensin converting enzyme in cardiovascular diseases

Mohácsi Attila, Lizanecz Erzsébet, I. Édes, I. Czuriga

Research output: Contribution to journalArticle

Abstract

The pathobiological aim of treatment with angiotensin converting enzyme inhibitor is to restore the balance between nitrogen-monoxide and angiotensin II due to inhibition of blood and tissue angiotensin converting enzyme. The clinical consquences of the inhibition of tissue angiotensin converting enzyme in patients with additionally high (HOPE) and low (EUROPA) cardiovascular risk without left ventricular dysfunction has already been demonstrated. Ramipril and the perindopril reduce the risk of combined end-point of these trials such as cardiovascular mortality, reinfarction and resuscitated sudden cardiac death. However, pharmacological and genetic differences in blocking of tissue angiotensin converting enzyme may influence the cardioprotective effect of various angiotensin converting enzyme inhibitors. Thus new, well-designed, controlled clinical trials are needed to determine the role of angiotensin converting enzyme inhibitor with different tissue angiotensin converting enzyme affinity in cardiovascular disease.

Original languageHungarian
Pages (from-to)843-849
Number of pages7
JournalLege Artis Medicinae
Volume14
Issue number12
Publication statusPublished - 2004

Fingerprint

Peptidyl-Dipeptidase A
Cardiovascular Diseases
Angiotensin-Converting Enzyme Inhibitors
Perindopril
Ramipril
Sudden Cardiac Death
Controlled Clinical Trials
Left Ventricular Dysfunction
Angiotensin II
Nitric Oxide
Pharmacology
Mortality
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A szöveti angiotenzinkonvertáló enzim szerepe a cardiovascularis betegségekben. / Attila, Mohácsi; Erzsébet, Lizanecz; Édes, I.; Czuriga, I.

In: Lege Artis Medicinae, Vol. 14, No. 12, 2004, p. 843-849.

Research output: Contribution to journalArticle

@article{6b303a258dc3404a8d97405a2ef990be,
title = "A sz{\"o}veti angiotenzinkonvert{\'a}l{\'o} enzim szerepe a cardiovascularis betegs{\'e}gekben",
abstract = "The pathobiological aim of treatment with angiotensin converting enzyme inhibitor is to restore the balance between nitrogen-monoxide and angiotensin II due to inhibition of blood and tissue angiotensin converting enzyme. The clinical consquences of the inhibition of tissue angiotensin converting enzyme in patients with additionally high (HOPE) and low (EUROPA) cardiovascular risk without left ventricular dysfunction has already been demonstrated. Ramipril and the perindopril reduce the risk of combined end-point of these trials such as cardiovascular mortality, reinfarction and resuscitated sudden cardiac death. However, pharmacological and genetic differences in blocking of tissue angiotensin converting enzyme may influence the cardioprotective effect of various angiotensin converting enzyme inhibitors. Thus new, well-designed, controlled clinical trials are needed to determine the role of angiotensin converting enzyme inhibitor with different tissue angiotensin converting enzyme affinity in cardiovascular disease.",
keywords = "Angiotensin converting enzyme inhibitors, Cardiovascular prevention, Tissue angiotensin converting enzyme",
author = "Moh{\'a}csi Attila and Lizanecz Erzs{\'e}bet and I. {\'E}des and I. Czuriga",
year = "2004",
language = "Hungarian",
volume = "14",
pages = "843--849",
journal = "Lege Artis Medicinae",
issn = "0866-4811",
publisher = "Literatura Medica Publishing House",
number = "12",

}

TY - JOUR

T1 - A szöveti angiotenzinkonvertáló enzim szerepe a cardiovascularis betegségekben

AU - Attila, Mohácsi

AU - Erzsébet, Lizanecz

AU - Édes, I.

AU - Czuriga, I.

PY - 2004

Y1 - 2004

N2 - The pathobiological aim of treatment with angiotensin converting enzyme inhibitor is to restore the balance between nitrogen-monoxide and angiotensin II due to inhibition of blood and tissue angiotensin converting enzyme. The clinical consquences of the inhibition of tissue angiotensin converting enzyme in patients with additionally high (HOPE) and low (EUROPA) cardiovascular risk without left ventricular dysfunction has already been demonstrated. Ramipril and the perindopril reduce the risk of combined end-point of these trials such as cardiovascular mortality, reinfarction and resuscitated sudden cardiac death. However, pharmacological and genetic differences in blocking of tissue angiotensin converting enzyme may influence the cardioprotective effect of various angiotensin converting enzyme inhibitors. Thus new, well-designed, controlled clinical trials are needed to determine the role of angiotensin converting enzyme inhibitor with different tissue angiotensin converting enzyme affinity in cardiovascular disease.

AB - The pathobiological aim of treatment with angiotensin converting enzyme inhibitor is to restore the balance between nitrogen-monoxide and angiotensin II due to inhibition of blood and tissue angiotensin converting enzyme. The clinical consquences of the inhibition of tissue angiotensin converting enzyme in patients with additionally high (HOPE) and low (EUROPA) cardiovascular risk without left ventricular dysfunction has already been demonstrated. Ramipril and the perindopril reduce the risk of combined end-point of these trials such as cardiovascular mortality, reinfarction and resuscitated sudden cardiac death. However, pharmacological and genetic differences in blocking of tissue angiotensin converting enzyme may influence the cardioprotective effect of various angiotensin converting enzyme inhibitors. Thus new, well-designed, controlled clinical trials are needed to determine the role of angiotensin converting enzyme inhibitor with different tissue angiotensin converting enzyme affinity in cardiovascular disease.

KW - Angiotensin converting enzyme inhibitors

KW - Cardiovascular prevention

KW - Tissue angiotensin converting enzyme

UR - http://www.scopus.com/inward/record.url?scp=77949994620&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949994620&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:77949994620

VL - 14

SP - 843

EP - 849

JO - Lege Artis Medicinae

JF - Lege Artis Medicinae

SN - 0866-4811

IS - 12

ER -